DE60235408D1 - Enzymatische spaltbare reagenzien zum spezifischen targeting von krankheitsherden - Google Patents

Enzymatische spaltbare reagenzien zum spezifischen targeting von krankheitsherden

Info

Publication number
DE60235408D1
DE60235408D1 DE60235408T DE60235408T DE60235408D1 DE 60235408 D1 DE60235408 D1 DE 60235408D1 DE 60235408 T DE60235408 T DE 60235408T DE 60235408 T DE60235408 T DE 60235408T DE 60235408 D1 DE60235408 D1 DE 60235408D1
Authority
DE
Germany
Prior art keywords
therapeutic reagent
diseases
enzymatic cleavage
specific targeting
host
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60235408T
Other languages
English (en)
Inventor
B P Morgan
C L Harris
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University College Cardiff Consultants Ltd
Cardiff University
Original Assignee
University College Cardiff Consultants Ltd
Cardiff University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0130104A external-priority patent/GB0130104D0/en
Priority claimed from GB0213619A external-priority patent/GB0213619D0/en
Application filed by University College Cardiff Consultants Ltd, Cardiff University filed Critical University College Cardiff Consultants Ltd
Application granted granted Critical
Publication of DE60235408D1 publication Critical patent/DE60235408D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE60235408T 2001-12-17 2002-11-27 Enzymatische spaltbare reagenzien zum spezifischen targeting von krankheitsherden Expired - Lifetime DE60235408D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0130104A GB0130104D0 (en) 2001-12-17 2001-12-17 Cleavable reagents for specific delivery to disease sites
GB0213619A GB0213619D0 (en) 2002-06-13 2002-06-13 Cleavable reagents for specific delivery to disease sites
PCT/GB2002/005371 WO2003051393A2 (en) 2001-12-17 2002-11-27 Enzymatic cleavable reagents for specific delivery to disease sites

Publications (1)

Publication Number Publication Date
DE60235408D1 true DE60235408D1 (de) 2010-04-01

Family

ID=26246877

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60235408T Expired - Lifetime DE60235408D1 (de) 2001-12-17 2002-11-27 Enzymatische spaltbare reagenzien zum spezifischen targeting von krankheitsherden

Country Status (8)

Country Link
US (1) US20060246066A1 (de)
EP (1) EP1461086B1 (de)
JP (1) JP4342314B2 (de)
AT (1) ATE457741T1 (de)
AU (1) AU2002366303B2 (de)
CA (1) CA2470643C (de)
DE (1) DE60235408D1 (de)
WO (1) WO2003051393A2 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005069726A2 (en) 2004-01-21 2005-08-04 Case Western Reserve University Hybrid and chimeric polypeptides that regulate activation of complement
JP2007099750A (ja) * 2005-02-25 2007-04-19 Hokkaido Univ 腫瘍組織で選択的に分解性を示す血中滞留性素子
CA2687395C (en) * 2007-05-03 2017-07-11 Medizinische Universitat Innsbruck Complement factor h-derived short consensus repeat-antibody constructs
EP3492488A1 (de) 2007-08-22 2019-06-05 The Regents of The University of California Aktivierbare bindende polypeptide und verfahren zu deren identifikation und anwendung
GB0820786D0 (en) * 2008-11-13 2008-12-24 Nordic Bioscience As Assessment of protein degradation by measurement of collagen fragments
CN102482347B (zh) 2009-01-12 2017-04-26 希托马克斯医疗有限责任公司 修饰抗体组合物及其制备和使用方法
CN102481341B (zh) 2009-02-23 2017-05-17 希托马克斯医疗有限公司 蛋白原及其使用方法
IL210093A0 (en) * 2010-12-19 2011-06-30 David Helman Membrane bound reporter molecules and their use in cell sorting
AU2013211824B2 (en) * 2012-01-27 2017-06-01 Gliknik Inc. Fusion proteins comprising IgG2 hinge domains
CN109053903B (zh) * 2018-09-12 2020-06-16 中国人民解放军沈阳军区总医院 一种重组人CREG-Fc融合蛋白的制备及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4671958A (en) * 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
US4867973A (en) * 1984-08-31 1989-09-19 Cytogen Corporation Antibody-therapeutic agent conjugates
US5094848A (en) * 1989-06-30 1992-03-10 Neorx Corporation Cleavable diphosphate and amidated diphosphate linkers
DE4236237A1 (de) * 1992-10-27 1994-04-28 Behringwerke Ag Prodrugs, ihre Herstellung und Verwendung als Arzneimittel
US5658592A (en) * 1994-05-13 1997-08-19 Kuraray Co., Ltd. Medical crosslinked polymer gel of carboxylic polysaccharide and diaminoalkane
US7147851B1 (en) * 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
CA2264610A1 (en) * 1996-11-05 1998-05-14 Bristol-Myers Squibb Company Branched peptide linkers
DE19701141C1 (de) * 1997-01-16 1998-04-09 Hoechst Ag Genkonstrukte für durch Proteasen aktivierbare Wirksubstanzen
MXPA02009019A (es) * 2000-03-15 2003-02-12 Du Pont Pharm Co Farmacos antineoplasticos de objetivo, que se desdoblan por la peptidasa y su uso terapeutico.

Also Published As

Publication number Publication date
WO2003051393A3 (en) 2003-10-16
AU2002366303B2 (en) 2007-09-20
CA2470643C (en) 2011-10-18
JP4342314B2 (ja) 2009-10-14
WO2003051393A2 (en) 2003-06-26
EP1461086A2 (de) 2004-09-29
CA2470643A1 (en) 2003-06-26
JP2005516016A (ja) 2005-06-02
AU2002366303A1 (en) 2003-06-30
US20060246066A1 (en) 2006-11-02
ATE457741T1 (de) 2010-03-15
EP1461086B1 (de) 2010-02-17

Similar Documents

Publication Publication Date Title
ES2151467T1 (es) Inhibicion de la actividad de la quinasa p38 por aril-ureas.
DE60041333D1 (de) Hen prostatkrebs exprimiert wird, und deren verwendungen
ES2154253T1 (es) Inhibicion de la actividad de la quinasa p38 utilizando ureas heterociclicas sustituidas.
CY1107995T1 (el) ΑΝΑΣΤΟΛΗ ΔΡΑΣΤΙΚΟΤΗΤΑΣ p38 ΚΙΝΑΣΗΣ ΧΡΗΣΙΜΟΠΟΙΩΝΤΑΣ ΑΡΥΛ ΚΑΙ ΕΤEPΟΑΡΥΛ ΥΠΟΚΑΤΕΣΤΗΜΕΝΕΣ ΕΤEPΟΚΥΚΛΙΚΕΣ ΟΥΡΙΕΣ
DE60235408D1 (de) Enzymatische spaltbare reagenzien zum spezifischen targeting von krankheitsherden
HUP0002095A2 (hu) Vegyületek prosztatarák immunterápiás kezelésére és alkalmazásuk
DK1053313T3 (da) Optimerede antisense oligonucleotider komplementære til DNA methyltransferase-sekvenser
WO2003030927A3 (fr) Utilisation de peptides analogues de la thymuline (pat) pour la fabrication de medicaments contre la douleur
DK1011723T3 (da) 88KDA tumorgen vækstfaktor og antagonister
MXPA05006034A (es) Proteina de duplicacion.
DE60142899D1 (de) Verbindungen für den transfer von oligonukleotiden
WO2003033648A3 (en) Imaging the activity of extracellular proteases in cells using mutant anthrax toxin protective antigens that are cleaved by specific extracellular proteases
DE50009838D1 (de) Humanes antibiotisches protein
ATE298246T1 (de) Aktiviertes protein c zur behandlung von pankreatitis
AU6987696A (en) The use of the wap of mmtv regulatory sequences for targeted expression of linked heterologous genes in human mammary cells, including human mammary carcinoma cells
WO2003087840A3 (en) Protein involved in cancer
BR0204160A (pt) Composto ciclopaladado, composição e unidade de dosagem, seus usos, método para inibir a atividade de proteìnas e enzimas e método de tratamento de distúrbios ou doenças associadas às mesmas e método de modulação do sistema imunológico
WO2002093127A3 (en) Methods and reagents for identifying insulin response modulators and therapeutic uses therefor
EA200700346A1 (ru) Бактериофаг- и профаг-специфические протеины в генной терапии рака
WO2002101076A3 (en) Methods for targeted expression of therapeutic nucleic acid
TW200716749A (en) Interferon-beta gene therapy using an improved, regulated expression system
DE60144204D1 (de) 84P2A9: Prostata- und hodenspezifisches Protein, das sehr stark bei Prostatakrebs vorkommt
ATE552887T1 (de) Tumorspezifischer vektor für die gentherapie
WO2004013152A3 (en) Novel targets for lithium therapy
ATE210990T1 (de) Therapeutischer viraler wirkstoff, welcher das fortschreiten von tumoren stoppt

Legal Events

Date Code Title Description
8364 No opposition during term of opposition